HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 1530413Generated: October 30, 2026
Potassium Acetate → 10-(2-Fluoropyridin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
https://huagongshe.com/reaction/1530413
Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Potassium Acetate | HCID 517044 | — |
| Reactant | 2-Fluoropyridine-3-boronic acid | HCID 2783270 | — |
| Reactant | 10-Bromo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine | HCID 58204739 | — |
| Catalyst | HCID 178418397 | HCID 178418397 | — |
| Solvent | Water | HCID 962 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | 10-(2-Fluoropyridin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine | HCID 58204896 | — |
Reaction Steps
To 10-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine (140 mg, 0.53 mmol) in DMF (20 mL) and water (2 mL) was added 2-Fluoropyridine-3-boronic acid (89 mg, 0.632 mml), Potassium acetate (207 mg, 2.11 mmol) and Tetrakis(triphenylphosphine)palladium (30 mg, 0.0264 mmol). The reaction mixture was degassed for 5 minutes, and heated at 100° C. overnight. LCMS showed desired product peak. The reaction was allowed to cool to room temperature, diluted with EtOAc, and filtered through a thin pad of celite. The filtrate was washed with water followed by brine, dried over MgSO4 and concentrated. The crude residue was purified by Prep HPLC to provide 10-(2-fluoropyridin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine. LC/MS (ESI+): m/z 282 (M+H)
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US09090628B2 |
|---|
| Source dataset | uspto-grants-2015_07 |
|---|
| ORD ID | ord-d7da839e78064c44aa51d180d416675f |
|---|
| Source note | uspto-grants-2015_07 |
|---|